Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | GABRA2 | P47869 | 13/20 | 0.57 |
| ▸ | GABRB2 | P47870 | 13/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24066038 | 0.88 | KDM4E (0.67) | KDM4EPOLBGABRA2GABRB2GAA | |
| SCHEMBL1647902 | 0.86 | KDM4E (0.76) | KDM4EPOLBGABRA2GABRB2GAA | |
| SCHEMBL3499130 | 0.85 | GABRA2 (0.62) | KDM4EPOLBGABRA2GABRB2PTGS2 | |
| SCHEMBL3499683 | 0.82 | KDM4E (0.59) | KDM4EPOLBGABRA2GABRB2PTGS2 | |
| SCHEMBL3498830 | 0.81 | PTGS1 (0.51) | KDM4EPOLBGABRA2GABRB2PTGS2 | |
| SCHEMBL1445451 | 0.81 | KDM4E (1.00) | KDM4EPOLBGAAALDH1A1HPGD | |
| SCHEMBL17437886 | 0.80 | KDM4E (0.78) | KDM4EPOLBGABRA2GABRB2GAA | |
| SCHEMBL7269185 | 0.80 | KDM4E (0.78) | KDM4EPOLBGABRA2GABRB2GAA | |
| SCHEMBL741904 | 0.79 | KDM4E (0.64) | KDM4EPOLBGABRA2GABRB2PTGS2 | |
| SCHEMBL20887367 | 0.79 | KDM4E (0.72) | KDM4EPOLBGABRA2GABRB2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | KDM4E 2059/4885POLB 4658/4885GABRA2 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.